News articles about Natus Medical (NASDAQ:BABY) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Natus Medical earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Natus Medical Incorporated (NASDAQ:BABY) Stock Closed Well Above Its 50 Day Moving Average – Highlight Press (highlightpress.com)
- Natus Medical Incorporated (BABY) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Natus Medical Incorporated (BABY) stock trades -4.59% lower to 200- SMA – Street Observer (press release) (streetobserver.com)
- Natus Medical Incorporated (NASDAQ:BABY) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Natus Medical, Inc. breached its 50 day moving average in a Bearish Manner : BABY-US : July 28, 2017 (finance.yahoo.com)
Several research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, April 4th. BidaskClub upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Benchmark Co. restated a “buy” rating and set a $48.00 price objective (down from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Finally, TheStreet lowered shares of Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. Natus Medical has an average rating of “Hold” and an average target price of $45.00.
Natus Medical (NASDAQ:BABY) traded down 1.81% on Friday, hitting $35.20. 378,665 shares of the stock traded hands. Natus Medical has a 52 week low of $33.15 and a 52 week high of $44.39. The firm has a market capitalization of $1.14 billion, a PE ratio of 61.86 and a beta of 0.95. The stock has a 50 day moving average of $36.69 and a 200 day moving average of $36.94.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The company had revenue of $122.20 million for the quarter, compared to analyst estimates of $121.99 million. During the same period last year, the firm earned $0.39 earnings per share. The firm’s revenue was up 27.3% on a year-over-year basis. Equities research analysts anticipate that Natus Medical will post $1.70 earnings per share for the current year.
In related news, insider James B. Hawkins acquired 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was acquired at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the completion of the acquisition, the insider now owns 578,023 shares of the company’s stock, valued at approximately $19,641,221.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James B. Hawkins acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The shares were bought at an average price of $33.81 per share, with a total value of $202,860.00. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Natus Medical (NASDAQ:BABY) Earns Daily Media Impact Rating of 0.19” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/07/30/natus-medical-nasdaqbaby-given-daily-coverage-optimism-score-of-0-19-updated-updated-updated.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.